Company news
Oxford Biodynamics Plc (LSE:OBD) news
Oxford Biodynamics Plc news releases on 6ix. Latest, Oct 1, 2026: Extension of Timetable in relation to Placing
Press releases & updates
Extension of Timetable in relation to Placing
October 1, 2026
Orion reveals link between five fatigue conditions
September 3, 2026
Partnership with Dubai London Clinics & Hospitals
August 13, 2026
First commercial agreement for EpiSwitch® Orion
July 28, 2026
US contract sales partnership
June 30, 2026
Board Appointment
April 15, 2026
OBD to present at PMWC 2026
March 3, 2026
Change of Nominated Adviser
February 17, 2026
Holding(s) in Company
January 27, 2026
Result of AGM
January 26, 2026
Board Change
January 26, 2026
Pilot Study Finds 30-Day Molecular Improvement in Prostate Health Following Intraprostatic Ozone Therapy, Tracked by the EpiSwitch® PSE Blood Test
January 22, 2026
Publication of 2025 Annual Report
December 22, 2025
Preliminary Results and Notice of AGM
December 16, 2025
Notice of Results
December 9, 2025
Statement re share price, update on EpiSwitch PSE
December 3, 2025
PDMR Dealing / Grant of Share Options
November 10, 2025
Result of General Meeting/PDMR Dealings
November 7, 2025
Fundraising, Posting of Circular & Notice of GM
October 22, 2025
OBD in New Report on NHS Prostate Cancer Screening
October 14, 2025
OBD and UEA develop test for Chronic Fatigue
October 8, 2025
Study confirms clinical utility of EpiSwitch CiRT
September 4, 2025
Collaboration with Google Cloud
August 13, 2025
GenomeWeb to host joint Agilent/OBD presentation
July 17, 2025
Pfizer study on EpiSwitch biomarkers
July 15, 2025
Interim Results
June 30, 2025
OBD’s Oxford Lab accredited by UKAS
May 9, 2025
Director/PDMR Shareholding
April 10, 2025
PDMR Dealing
April 2, 2025
Board Changes
March 17, 2025
Expansion of OBD/Bupa UK insurance partnership
March 13, 2025
Publication of 2024 Annual Report
March 5, 2025
Notice of Preliminary Results
February 21, 2025
OBD partners with Regina Maria in Romania
February 12, 2025
CRC Test Accurately Detects Cancer and Polyps
February 5, 2025
Result of GM and Director Dealings
January 31, 2025
CiRT: Real World Data Presented at ASCO-GI
January 23, 2025
Result of WRAP Retail Offer
January 17, 2025
Result of Placing and Subscription
January 15, 2025
WRAP Retail Offer
January 14, 2025
Proposed Fundraising
January 14, 2025
Issue of shares, Director / PDMR holdings and TVR
December 24, 2024
Shareholder Loan and Related Party Transaction
December 19, 2024
Directorate Change, Funding Update & Joint Broker
December 16, 2024
Response to Share Price Movement
December 3, 2024
Director / PDMR holdings and Total Voting Rights
October 28, 2024
Prognostic Covid Severity Test Study Published
October 25, 2024
CiRT Receives Clinical Approval from NYS CLEP
October 22, 2024
Commercial update for FY24
October 14, 2024
CIRRP Award Update
October 7, 2024